Global Meningitis Vaccine

Meningitis Vaccine Comprehensive Study by Type (Meningitis A+C, Meningitis ACWY135, Meningitis B), Application (Medical Care, Healthy, Hospital), Route of Administration (Intramuscular and Subcutaneous Administration, Oral Administration, Other Routes of Administration), Diagnosis (Blood cultures, Imaging (CT Scan, MRI and X-Rays), Spinal tap (lumbar puncture)) Players and Region - Global Market Outlook to 2030

Meningitis Vaccine Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Meningitis Vaccine
Meningitis and encephalitis are important causes of admissions and mortality for children in Zambia. Bacterial meningitis is the most serious type of meningitis that can lead to death or permanent disability. It affects the meninges, the membranes that surround the brain and spinal cord and protects the central nervous system (CNS), together with the cerebrospinal fluid. In bacterial meningitis, approximately 80 percent of all cases are acute bacterial meningitis. It can be life-threatening because it affects the tissues around the brain to swell. This can result in paralysis or stroke. Vaccine is an antigenic substance prepared to kill microorganisms, living attenuated organisms, or living fully virulent organisms that is administered to produce or artificially increase immunity to a particular disease. The rising prevalence of several infectious diseases is rising demand for vaccine market. The healthcare infrastructure and high awareness levels of the benefits of immunization are the major factors boosting the market growth.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


There are relatively very few vaccine manufacturers that meet the international standard, due to which the individual vaccine manufacturer, the market become monopolies or oligopoly either by product or presentation. Very, few suppliers and production capacities lead to a tenuous balance between demand and supply in many individual vaccine markets. Analyst at AMA Research estimates that United States and Chinese Players will contribute the maximum growth to Global Meningitis Vaccine market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKline (United Kingdom), Baxter International Inc. (United States), Sanofi S.A. (France), Merck (Germany), Novartis (Switzerland), Pfizer (United States), Hualan (China), Zhejiang Tianyuan (China) and Beijing Tiantan Biological (China) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Crucell (Netherland), Medimmune (United States) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Meningitis Vaccine market by Type (Meningitis A+C, Meningitis ACWY135 and Meningitis B), Application (Medical Care, Healthy and Hospital) and Region.



On the basis of geography, the market of Meningitis Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Intramuscular and Subcutaneous Administration will boost the Meningitis Vaccine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. Blood cultures will boost the Meningitis Vaccine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Huge Investments by the Major Players

Market Growth Drivers:
Increased Prevalence of Bacterial Meningitis

Challenges:
Stringent Government Rules and Regulations

Restraints:
High Cost Involved in Vaccine Development

Opportunities:
Growth in the Healthcare Industry, Increasing Research and Development Activities and Increasing Demand for Effective Treatment

Market Leaders and their expansionary development strategies
In August 2022, GSK plc., announced it has completed the acquisition of Affinivax, Inc (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge (Boston, Massachusetts). Affinivax has pioneered the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines.
In September 2022, Pfizer Inc., announced positive top-line results from the pivotal Phase 3 trial (NCT04440163) assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age.
WHO ensures the safety and quality of vaccines and works closely on global standards which are developed and made readily available. WHO provides norms and standard and give advice to procurement agencies and countries on the acceptability, in principle of vaccines. It has also established the Global Advisory committee on vaccine safety which includes national experts and authority to support vaccine safety.

Key Target Audience
Manufacturers and suppliers of vaccines, Research and development companies, Medical research laboratories, Academic medical centers and universities, Research and consulting firms and Venture capital firms

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Meningitis A+C
  • Meningitis ACWY135
  • Meningitis B
By Application
  • Medical Care
  • Healthy
  • Hospital
By Route of Administration
  • Intramuscular and Subcutaneous Administration
  • Oral Administration
  • Other Routes of Administration

By Diagnosis
  • Blood cultures
  • Imaging (CT Scan, MRI and X-Rays)
  • Spinal tap (lumbar puncture)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Bacterial Meningitis
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Huge Investments by the Major Players
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Meningitis Vaccine, by Type, Application, Route of Administration, Diagnosis and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Meningitis Vaccine (Value)
      • 5.2.1. Global Meningitis Vaccine by: Type (Value)
        • 5.2.1.1. Meningitis A+C
        • 5.2.1.2. Meningitis ACWY135
        • 5.2.1.3. Meningitis B
      • 5.2.2. Global Meningitis Vaccine by: Application (Value)
        • 5.2.2.1. Medical Care
        • 5.2.2.2. Healthy
        • 5.2.2.3. Hospital
      • 5.2.3. Global Meningitis Vaccine by: Route of Administration (Value)
        • 5.2.3.1. Intramuscular and Subcutaneous Administration
        • 5.2.3.2. Oral Administration
        • 5.2.3.3. Other Routes of Administration
      • 5.2.4. Global Meningitis Vaccine by: Diagnosis (Value)
        • 5.2.4.1. Blood cultures
        • 5.2.4.2. Imaging (CT Scan, MRI and X-Rays)
        • 5.2.4.3. Spinal tap (lumbar puncture)
      • 5.2.5. Global Meningitis Vaccine Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Meningitis Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Baxter International Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi S.A. (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Hualan (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Zhejiang Tianyuan (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Beijing Tiantan Biological (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Meningitis Vaccine Sale, by Type, Application, Route of Administration, Diagnosis and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Meningitis Vaccine (Value)
      • 7.2.1. Global Meningitis Vaccine by: Type (Value)
        • 7.2.1.1. Meningitis A+C
        • 7.2.1.2. Meningitis ACWY135
        • 7.2.1.3. Meningitis B
      • 7.2.2. Global Meningitis Vaccine by: Application (Value)
        • 7.2.2.1. Medical Care
        • 7.2.2.2. Healthy
        • 7.2.2.3. Hospital
      • 7.2.3. Global Meningitis Vaccine by: Route of Administration (Value)
        • 7.2.3.1. Intramuscular and Subcutaneous Administration
        • 7.2.3.2. Oral Administration
        • 7.2.3.3. Other Routes of Administration
      • 7.2.4. Global Meningitis Vaccine by: Diagnosis (Value)
        • 7.2.4.1. Blood cultures
        • 7.2.4.2. Imaging (CT Scan, MRI and X-Rays)
        • 7.2.4.3. Spinal tap (lumbar puncture)
      • 7.2.5. Global Meningitis Vaccine Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Meningitis Vaccine: by Type(USD Million)
  • Table 2. Meningitis Vaccine Meningitis A+C , by Region USD Million (2018-2023)
  • Table 3. Meningitis Vaccine Meningitis ACWY135 , by Region USD Million (2018-2023)
  • Table 4. Meningitis Vaccine Meningitis B , by Region USD Million (2018-2023)
  • Table 5. Meningitis Vaccine: by Application(USD Million)
  • Table 6. Meningitis Vaccine Medical Care , by Region USD Million (2018-2023)
  • Table 7. Meningitis Vaccine Healthy , by Region USD Million (2018-2023)
  • Table 8. Meningitis Vaccine Hospital , by Region USD Million (2018-2023)
  • Table 9. Meningitis Vaccine: by Route of Administration(USD Million)
  • Table 10. Meningitis Vaccine Intramuscular and Subcutaneous Administration , by Region USD Million (2018-2023)
  • Table 11. Meningitis Vaccine Oral Administration , by Region USD Million (2018-2023)
  • Table 12. Meningitis Vaccine Other Routes of Administration , by Region USD Million (2018-2023)
  • Table 13. Meningitis Vaccine: by Diagnosis(USD Million)
  • Table 14. Meningitis Vaccine Blood cultures , by Region USD Million (2018-2023)
  • Table 15. Meningitis Vaccine Imaging (CT Scan, MRI and X-Rays) , by Region USD Million (2018-2023)
  • Table 16. Meningitis Vaccine Spinal tap (lumbar puncture) , by Region USD Million (2018-2023)
  • Table 17. South America Meningitis Vaccine, by Country USD Million (2018-2023)
  • Table 18. South America Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 19. South America Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 20. South America Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 21. South America Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 22. Brazil Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 23. Brazil Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 24. Brazil Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 25. Brazil Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 26. Argentina Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 27. Argentina Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 28. Argentina Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 29. Argentina Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 30. Rest of South America Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 31. Rest of South America Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 32. Rest of South America Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 33. Rest of South America Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 34. Asia Pacific Meningitis Vaccine, by Country USD Million (2018-2023)
  • Table 35. Asia Pacific Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 36. Asia Pacific Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 37. Asia Pacific Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 38. Asia Pacific Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 39. China Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 40. China Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 41. China Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 42. China Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 43. Japan Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 44. Japan Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 45. Japan Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 46. Japan Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 47. India Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 48. India Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 49. India Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 50. India Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 51. South Korea Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 52. South Korea Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 53. South Korea Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 54. South Korea Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 55. Taiwan Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 56. Taiwan Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 57. Taiwan Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 58. Taiwan Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 59. Australia Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 60. Australia Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 61. Australia Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 62. Australia Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 67. Europe Meningitis Vaccine, by Country USD Million (2018-2023)
  • Table 68. Europe Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 69. Europe Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 70. Europe Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 71. Europe Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 72. Germany Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 73. Germany Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 74. Germany Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 75. Germany Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 76. France Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 77. France Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 78. France Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 79. France Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 80. Italy Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 81. Italy Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 82. Italy Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 83. Italy Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 84. United Kingdom Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 85. United Kingdom Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 86. United Kingdom Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 87. United Kingdom Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 88. Netherlands Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 89. Netherlands Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 90. Netherlands Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 91. Netherlands Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 92. Rest of Europe Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 93. Rest of Europe Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 94. Rest of Europe Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 95. Rest of Europe Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 96. MEA Meningitis Vaccine, by Country USD Million (2018-2023)
  • Table 97. MEA Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 98. MEA Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 99. MEA Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 100. MEA Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 101. Middle East Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 102. Middle East Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 103. Middle East Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 104. Middle East Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 105. Africa Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 106. Africa Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 107. Africa Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 108. Africa Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 109. North America Meningitis Vaccine, by Country USD Million (2018-2023)
  • Table 110. North America Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 111. North America Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 112. North America Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 113. North America Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 114. United States Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 115. United States Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 116. United States Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 117. United States Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 118. Canada Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 119. Canada Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 120. Canada Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 121. Canada Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 122. Mexico Meningitis Vaccine, by Type USD Million (2018-2023)
  • Table 123. Mexico Meningitis Vaccine, by Application USD Million (2018-2023)
  • Table 124. Mexico Meningitis Vaccine, by Route of Administration USD Million (2018-2023)
  • Table 125. Mexico Meningitis Vaccine, by Diagnosis USD Million (2018-2023)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Meningitis Vaccine: by Type(USD Million)
  • Table 136. Meningitis Vaccine Meningitis A+C , by Region USD Million (2025-2030)
  • Table 137. Meningitis Vaccine Meningitis ACWY135 , by Region USD Million (2025-2030)
  • Table 138. Meningitis Vaccine Meningitis B , by Region USD Million (2025-2030)
  • Table 139. Meningitis Vaccine: by Application(USD Million)
  • Table 140. Meningitis Vaccine Medical Care , by Region USD Million (2025-2030)
  • Table 141. Meningitis Vaccine Healthy , by Region USD Million (2025-2030)
  • Table 142. Meningitis Vaccine Hospital , by Region USD Million (2025-2030)
  • Table 143. Meningitis Vaccine: by Route of Administration(USD Million)
  • Table 144. Meningitis Vaccine Intramuscular and Subcutaneous Administration , by Region USD Million (2025-2030)
  • Table 145. Meningitis Vaccine Oral Administration , by Region USD Million (2025-2030)
  • Table 146. Meningitis Vaccine Other Routes of Administration , by Region USD Million (2025-2030)
  • Table 147. Meningitis Vaccine: by Diagnosis(USD Million)
  • Table 148. Meningitis Vaccine Blood cultures , by Region USD Million (2025-2030)
  • Table 149. Meningitis Vaccine Imaging (CT Scan, MRI and X-Rays) , by Region USD Million (2025-2030)
  • Table 150. Meningitis Vaccine Spinal tap (lumbar puncture) , by Region USD Million (2025-2030)
  • Table 151. South America Meningitis Vaccine, by Country USD Million (2025-2030)
  • Table 152. South America Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 153. South America Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 154. South America Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 155. South America Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 156. Brazil Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 157. Brazil Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 158. Brazil Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 159. Brazil Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 160. Argentina Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 161. Argentina Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 162. Argentina Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 163. Argentina Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 164. Rest of South America Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 165. Rest of South America Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 166. Rest of South America Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 167. Rest of South America Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 168. Asia Pacific Meningitis Vaccine, by Country USD Million (2025-2030)
  • Table 169. Asia Pacific Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 170. Asia Pacific Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 171. Asia Pacific Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 172. Asia Pacific Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 173. China Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 174. China Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 175. China Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 176. China Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 177. Japan Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 178. Japan Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 179. Japan Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 180. Japan Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 181. India Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 182. India Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 183. India Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 184. India Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 185. South Korea Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 186. South Korea Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 187. South Korea Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 188. South Korea Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 189. Taiwan Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 190. Taiwan Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 191. Taiwan Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 192. Taiwan Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 193. Australia Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 194. Australia Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 195. Australia Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 196. Australia Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 197. Rest of Asia-Pacific Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 198. Rest of Asia-Pacific Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 199. Rest of Asia-Pacific Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 200. Rest of Asia-Pacific Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 201. Europe Meningitis Vaccine, by Country USD Million (2025-2030)
  • Table 202. Europe Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 203. Europe Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 204. Europe Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 205. Europe Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 206. Germany Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 207. Germany Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 208. Germany Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 209. Germany Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 210. France Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 211. France Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 212. France Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 213. France Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 214. Italy Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 215. Italy Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 216. Italy Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 217. Italy Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 218. United Kingdom Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 219. United Kingdom Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 220. United Kingdom Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 221. United Kingdom Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 222. Netherlands Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 223. Netherlands Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 224. Netherlands Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 225. Netherlands Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 226. Rest of Europe Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 227. Rest of Europe Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 228. Rest of Europe Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 229. Rest of Europe Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 230. MEA Meningitis Vaccine, by Country USD Million (2025-2030)
  • Table 231. MEA Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 232. MEA Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 233. MEA Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 234. MEA Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 235. Middle East Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 236. Middle East Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 237. Middle East Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 238. Middle East Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 239. Africa Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 240. Africa Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 241. Africa Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 242. Africa Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 243. North America Meningitis Vaccine, by Country USD Million (2025-2030)
  • Table 244. North America Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 245. North America Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 246. North America Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 247. North America Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 248. United States Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 249. United States Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 250. United States Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 251. United States Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 252. Canada Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 253. Canada Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 254. Canada Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 255. Canada Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 256. Mexico Meningitis Vaccine, by Type USD Million (2025-2030)
  • Table 257. Mexico Meningitis Vaccine, by Application USD Million (2025-2030)
  • Table 258. Mexico Meningitis Vaccine, by Route of Administration USD Million (2025-2030)
  • Table 259. Mexico Meningitis Vaccine, by Diagnosis USD Million (2025-2030)
  • Table 260. Research Programs/Design for This Report
  • Table 261. Key Data Information from Secondary Sources
  • Table 262. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Meningitis Vaccine: by Type USD Million (2018-2023)
  • Figure 5. Global Meningitis Vaccine: by Application USD Million (2018-2023)
  • Figure 6. Global Meningitis Vaccine: by Route of Administration USD Million (2018-2023)
  • Figure 7. Global Meningitis Vaccine: by Diagnosis USD Million (2018-2023)
  • Figure 8. South America Meningitis Vaccine Share (%), by Country
  • Figure 9. Asia Pacific Meningitis Vaccine Share (%), by Country
  • Figure 10. Europe Meningitis Vaccine Share (%), by Country
  • Figure 11. MEA Meningitis Vaccine Share (%), by Country
  • Figure 12. North America Meningitis Vaccine Share (%), by Country
  • Figure 13. Global Meningitis Vaccine share by Players 2023 (%)
  • Figure 14. Global Meningitis Vaccine share by Players (Top 3) 2023(%)
  • Figure 15. Global Meningitis Vaccine share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 19. Baxter International Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Baxter International Inc. (United States) Revenue: by Geography 2023
  • Figure 21. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 22. Sanofi S.A. (France) Revenue: by Geography 2023
  • Figure 23. Merck (Germany) Revenue, Net Income and Gross profit
  • Figure 24. Merck (Germany) Revenue: by Geography 2023
  • Figure 25. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Novartis (Switzerland) Revenue: by Geography 2023
  • Figure 27. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 28. Pfizer (United States) Revenue: by Geography 2023
  • Figure 29. Hualan (China) Revenue, Net Income and Gross profit
  • Figure 30. Hualan (China) Revenue: by Geography 2023
  • Figure 31. Zhejiang Tianyuan (China) Revenue, Net Income and Gross profit
  • Figure 32. Zhejiang Tianyuan (China) Revenue: by Geography 2023
  • Figure 33. Beijing Tiantan Biological (China) Revenue, Net Income and Gross profit
  • Figure 34. Beijing Tiantan Biological (China) Revenue: by Geography 2023
  • Figure 35. Global Meningitis Vaccine: by Type USD Million (2025-2030)
  • Figure 36. Global Meningitis Vaccine: by Application USD Million (2025-2030)
  • Figure 37. Global Meningitis Vaccine: by Route of Administration USD Million (2025-2030)
  • Figure 38. Global Meningitis Vaccine: by Diagnosis USD Million (2025-2030)
  • Figure 39. South America Meningitis Vaccine Share (%), by Country
  • Figure 40. Asia Pacific Meningitis Vaccine Share (%), by Country
  • Figure 41. Europe Meningitis Vaccine Share (%), by Country
  • Figure 42. MEA Meningitis Vaccine Share (%), by Country
  • Figure 43. North America Meningitis Vaccine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline (United Kingdom)
  • Baxter International Inc. (United States)
  • Sanofi S.A. (France)
  • Merck (Germany)
  • Novartis (Switzerland)
  • Pfizer (United States)
  • Hualan (China)
  • Zhejiang Tianyuan (China)
  • Beijing Tiantan Biological (China)
Additional players considered in the study are as follows:
Crucell (Netherland) , Medimmune (United States) , Others
Select User Access Type

Key Highlights of Report


Apr 2024 214 Pages 60 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Meningitis Vaccine Quantitative research analysis
Global Meningitis Vaccine Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GlaxoSmithKline (United Kingdom), Baxter International Inc. (United States), Sanofi S.A. (France), Merck (Germany), Novartis (Switzerland), Pfizer (United States), Hualan (China), Zhejiang Tianyuan (China) and Beijing Tiantan Biological (China) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Huge Investments by the Major Players" is seen as one of major influencing trends for Meningitis Vaccine Market during projected period 2023-2030.
The Meningitis Vaccine market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Meningitis Vaccine Report?

Have a Query? Click Here

Other Related Reports

Rosuvastatin Comprehensive Study by Type (High Purity, Low Purity), Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Stores), Form Type (Capsule, Tablet), Dosage (5 ...
$ 3350
Xeloda Comprehensive Study by Application (Colon Cancer, Rectal Cancer, Breast Cancer, Gastric Cancer, Others), Strength (500mg, 100mg) Players and Region - Global Market Outlook to 2026
$ 3500
Wound Cleanser Solutions Comprehensive Study by Type (Saline, Polyhexethylene biguanide (PHMB), Hypochlorous Acid (HOCl), Chlorhexidine solution, Acetic acid, Superoxidised solution, Hydrogen peroxid...
$ 3650
Feed Phytogenics Comprehensive Study by Product Type (Essential oils, Herbs & spices, Oleoresins, Others), Livestock (Poultry, Swine, Ruminant, Aquatic, Equine, Others), Function (Palatability Enha...
$ 3650
Streptokinase Comprehensive Study by Application (Myocardial Infarction (MI), Deep vein thrombosis, Pulmonary embolism, Others), Way of ordering (Walk-in, Application, Online) Players and Region - Gl...
$ 3500
Anti-Aging Drugs Comprehensive Study by Application (Skin and Hair, Skeletal and Muscles, Age Related Disorders, Others), Therapy (Homeopathic, Allopathic), Drug Class (Serums and Supplement, Antiox...
$ 3350